Parcom Capital has acquired Viroclinics Biosciences, a CRO based in The Netherlands that specializes in testing new vaccines and drugs in the clinical trial stages prior to market launch. Viroclinics employs more than 100 people and works with clients around the world. Viroclinics tests around 90% of all anti-influenza medications developed worldwide. The company expects to see further growth in other fields of virology in the coming years.   Bob van Gemen, chief executive officer of Virocl...